Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Microdosing Psychedelics to Improve Mood

To see complete record on, please visit this link

Id: NCT05259943

Organisation Name: University of Toronto

Overal Status: Not yet recruiting

Start Date: April 2022

Last Update: March 29, 2022

Lead Sponsor: Rotem Petranker

Brief Summary: The purpose of this trial is to examine the safety and efficacy of small (2mg) sub hallucinogenic doses of psilocybin in people with Persistent Depressive Disorder.

  • Persistent Depressive Disorder, Dysthymia

Total execution time in seconds: 0.19801712036133